ADG116 + pembrolizumab

ADG116 + pembrolizumab is an investigational combination therapy comprising two monoclonal antibodies: **ADG116**, a selective human anti-CTLA-4 IgG1 monoclonal antibody developed by Adagene, and **pembrolizumab**, an FDA-approved anti-programmed cell death-1 (PD-1) antibody (marketed as Keytruda by Merck Sharp & Dohme). This combination is being evaluated in patients with advanced or metastatic solid tumors who have progressed after standard therapies. ADG116 targets cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) to enhance T-cell immune responses, while pembrolizumab blocks PD-1 to prevent immune suppression by tumors. The goal of this combination is to enhance antitumor immunity by simultaneously inhibiting two immune checkpoint pathways[1][4].

Other names

ADG-116ADG116ADG 116Firastotug